A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
Status:
Terminated
Trial end date:
2018-07-17
Target enrollment:
Participant gender:
Summary
The objectives of this time-to-event study were to assess the efficacy and safety of
eculizumab as compared with placebo in participants with neuromyelitis optica spectrum
disorder (NMOSD) who were anti-aquaporin-4 (AQP4) antibody-positive.